Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

HC Wainwright Rodman & Renshaw Global Investment Conference
September 5, 2018 -
September 6, 2018
8:00am - 5:00pm EDT